Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

PURPOSE: The Phase 3 ENDEAVOUR study evaluated revusiran, an investigational RNA interference therapeutic targeting hepatic transthyretin (TTR) production, for treating cardiomyopathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. METHODS: Patients with hATTR amyloidosis with cardi...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovasc Drugs Ther
Main Authors: Judge, Daniel P., Kristen, Arnt V., Grogan, Martha, Maurer, Mathew S., Falk, Rodney H., Hanna, Mazen, Gillmore, Julian, Garg, Pushkal, Vaishnaw, Akshay K., Harrop, Jamie, Powell, Christine, Karsten, Verena, Zhang, Xiaoping, Sweetser, Marianne T., Vest, John, Hawkins, Philip N.
Format: Artigo
Language:Inglês
Published: Springer US 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7242280/
https://ncbi.nlm.nih.gov/pubmed/32062791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-019-06919-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items